asthma
发表于 2025-3-23 12:16:44
http://reply.papertrans.cn/95/9427/942635/942635_11.png
Increment
发表于 2025-3-23 17:21:07
http://reply.papertrans.cn/95/9427/942635/942635_12.png
Trypsin
发表于 2025-3-23 19:01:34
http://reply.papertrans.cn/95/9427/942635/942635_13.png
BINGE
发表于 2025-3-23 23:16:42
http://reply.papertrans.cn/95/9427/942635/942635_14.png
delta-waves
发表于 2025-3-24 04:34:46
http://reply.papertrans.cn/95/9427/942635/942635_15.png
–DOX
发表于 2025-3-24 08:30:23
http://reply.papertrans.cn/95/9427/942635/942635_16.png
Admonish
发表于 2025-3-24 11:42:59
Albert Tillmann-Davalos v Acknowledgments To our sponsors, U.S.V. Pharmaceutical Corp., Pfizer Pharmaceuticals, Ames Company, Hoechst, Frankfurt; supporters, Boehringer, Manhe978-1-4615-9112-2978-1-4615-9110-8Series ISSN 0065-2598 Series E-ISSN 2214-8019
genuine
发表于 2025-3-24 18:10:05
Albert Tillmannn addition, there are chapters dedicated to the postoperative course of these patients, as well as their quality of life, with indications for the correct follow-up and treatment of relapses.978-88-470-5613-8978-88-470-2330-7Series ISSN 2280-9848 Series E-ISSN 2281-0854
Exposure
发表于 2025-3-24 21:16:53
http://reply.papertrans.cn/95/9427/942635/942635_19.png
conjunctiva
发表于 2025-3-25 00:26:19
Albert Tillmannproducts. In this chapter, the history of anti-inflammatory drug development in CF will be reviewed first, and then an update on current studies of anti-inflammatory drugs in the CF pipeline will be provided.